- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
NEJM: Neutralizing Effect of Inactivated Vaccine Against COVID-19 Mutants
NEJM: Neutralizing Effect of Inactivated Vaccine Against COVID-19 Mutants. NEJM: The latest results of the neutralization efficacy of the inactivated vaccine against the new coronavirus mutant virus are released.
On April 6, 2021, the most well-known medical journal, the New England Journal of Medicine (NEJM), published a communication article by Chinese scholars, and conducted research on this most critical issue, which is of great significance.
The study verified the neutralizing activity of two domestically-made inactivated vaccines, BBIBP-CorV and CoronaVac from Kexing (SINOVAC), against the British mutant B.1.1.7 and the South African mutant B.1.351.
The study selected 50 sera of vaccinators who had been vaccinated with Sinopharm or Kexing vaccine twice. The neutralization titers were first compared with the sera of 34 survivors 5 months after infection. The serum neutralization activity of the two vaccines was roughly the same, suggesting that the two vaccines induced low-level antibody responses after inoculation.
It is worth noting that for the wild-type pseudovirus strain, 4 of the 34 recovered patients (11.8%), 6 (24%) of the 25 Sinopharm vaccinators, and 4 of the 25 Kexing vaccine vaccinators ( 16%) No neutralizing potency was detected.
(Figure 1. Image source: NEJM)
Neutralizing activity of the recovered patient’s serum for the mutant strain
For mutant strains, compared with wild-type strains, recovered patients’ serum neutralized D614G pseudovirus more effectively, neutralized B.1.1.7 mutation equivalently, and neutralized B.1.1.351 significantly weakened. On 9/30 (30%), the serum of recovered patients was completely ineffective in neutralizing B.1.1.351.
China SINOPHARM BBIBP-CorV vaccine
For mutant strains, there was no significant change in neutralizing GMTs compared with wild-type strains, but 20/25 (80%) of SINOPHARM vaccine BBIBP-CorV vaccinated serum was completely or partially ineffective when neutralizing B.1.1.351.
China Kexing (SINOVAC) CoronaVac vaccine
Compared with the wild-type strain, the neutralization of GMTs against B.1.1.7 and B.1.1.351 was significantly reduced, and most of the sera of CoronaVac vaccinators of Coxing vaccine were completely or partially ineffective in neutralizing the B.1.1.351 mutation. .
The results suggest that the neutralizing activity of B.1.1.7 in the serum of China’s survivors of COVID-19 infection and SINOPHARM vaccines has not changed significantly, and the Kexing vaccine has declined significantly. The serum neutralization activity of recovered B.1.351 decreased to 0.5, Sinopharm decreased to 0.4, and Kexing decreased most significantly, to 0.3.
(source:internet, reference only)